Legend Biotech CEO and leadership

Dr Huang served as CFO since July, 2019 and was appointed CEO and CFO November, 2020. He brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Most recently, Dr Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr Huang has been a biotech analyst since 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector.

Prior to his Wall Street career, Dr Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications. Dr Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University, New York, USA. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.

Dr Fan is a co-founder of Legend Biotech and its Chief Scientific Officer since 2014. Dr Fan has been published in numerous peer-reviewed academic journals, including a major revision in the clinical guidelines of pediatric organ transplantation published in Nature Medicine. Dr Fan was also awarded a “New Key Opinion Leader” award by The International Society of Transplantation.

Dr Fan earned his Doctor of Medicine degree at Xi’an Jiaotong University, China, and completed his surgical residency at the Jiaotong University Kidney Transplant Center, China. Dr Fan later obtained his Doctor of Philosophy in applied immunology at Hiroshima University, Japan, and completed postdoctoral training in the field of human B-cell tolerance at the Hospital for Sick Children at the University of Toronto, Canada.

Dr Fan is a co-founder of Legend Biotech and its Chief Scientific Officer since 2014. Dr Fan has been published in numerous peer-reviewed academic journals, including a major revision in the clinical guidelines of pediatric organ transplantation published in Nature Medicine. Dr Fan was also awarded a “New Key Opinion Leader” award by The International Society of Transplantation.

Dr Fan earned his Doctor of Medicine degree at Xi’an Jiaotong University, China, and completed his surgical residency at the Jiaotong University Kidney Transplant Center, China. Dr Fan later obtained his Doctor of Philosophy in applied immunology at Hiroshima University, Japan, and completed postdoctoral training in the field of human B-cell tolerance at the Hospital for Sick Children at the University of Toronto, Canada.

Dr Huang served as CFO since July, 2019 and was appointed CEO and CFO November, 2020. He brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Most recently, Dr Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr Huang has been a biotech analyst since 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector.

Prior to his Wall Street career, Dr Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications. Dr Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University, New York, USA. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.